Scribd
Upload
85 views22 pages

CLACIDO

Amoxicillin is susceptible to degradation by beta-lactamase, but clavulanic acid inhibits beta-lactamase and protects amoxicillin. Clavulanic acid combined with amoxicillin in the drug CLACIDO provides synergistic action against bacterial infections by inhibiting beta-lactamase and preventing degradation of amoxicillin. CLACIDO is indicated for upper and lower respiratory, genitourinary, skin and soft tissue, bone and joint infections, and other infections.

Uploaded by

Sergel Capsule
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
85 views22 pages

CLACIDO

Amoxicillin is susceptible to degradation by beta-lactamase, but clavulanic acid inhibits beta-lactamase and protects amoxicillin. Clavulanic acid combined with amoxicillin in the drug CLACIDO provides synergistic action against bacterial infections by inhibiting beta-lactamase and preventing degradation of amoxicillin. CLACIDO is indicated for upper and lower respiratory, genitourinary, skin and soft tissue, bone and joint infections, and other infections.

Uploaded by

Sergel Capsule
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
You are on page 1/ 22

Why combination needed?

Amoxicillin is susceptible to degradation by beta-lactamase.


Clavulanic acid is a beta lactamase inhibitor.

Clavulanic Acid inhibit beta-lactamase and protect beta-lactam antibiotic


Product brief
Brand CLACIDO

Generic Amoxicillin+Clavulanic Acid

CLACIDO tablet: 375 mg, 625 mg & 1 g

Strength CLACIDO PFS: 100 ml (125 mg/5 ml), 35 ml bid PFS (400 mg/5 ml)

CLACIDO IV injection: 0.6 g & 1.2 g

Dosage Form Tablet, PFS & IV injection

Brand Slogan Synergistic action against infections

Pregnancy Category US-FDA pregnancy category “B”

Recommended Age From o months of age


Approved price
Strength Dosage form Pack size Tk./pack Unit prize

375 mg Tablet (3X6’s) 450.00 25

625 mg Tablet (3X6’s) 576.00 32

1g Tablet (2X6’s) 540.00 45

100 ml PFS (1X1’s) 220.00

35 ml PFS (1X1’s) 100.00

1.2 g Inj. (1X1’s) 300.00

0.6 g Inj. (1X1’s) 150.00


Indications
 Upper respiratory tract infections
 Lower respiratory tract infections
 Genito-urinary tract infections
 Skin and soft tissue infections
 Bone and joint infections
 Other infections e.g. intra-abdominal sepsis, septic abortion, Puerperal
sepsis, septicaemia, peritonitis, Post-surgical infections
General Dosage guideline:
Pediatric dosage
Strength &
Adult dosage <12 weeks 12 weeks (3 months)
dosage form 0-12 years:
(<3 months): and Older:
12 hourly or 8 hourly
625 mg tablet
(severe infections)
375 mg tablet 8 hourly
12 hourly
1g tablet
(severe infections)
Severe infections:
45 mg/kg/day
every 12 hours or
30 mg/kg/day
40 mg/kg/day every 8 hours
PFS divided every
Less severe infections:
12 hours
25 mg/kg/day every 12 hours or 20
mg/kg/day
every 8 hours

1.2 g 8 hourly or 30 mg/kg 8 hourly or


IV inj. 6 hour intervals in severe 6 hour intervals in
infections severe infections
Target doctors: (According to 4p)

• 1st line target doctors: Medicine, ENT, Child, Chest & Gynecologist

• 2nd line target doctors: GP

• 3rd line target doctors: Surgeon, Cardiologist, Diabetologist, Dentist,

Orthopedist, Skin specialist & RMP


Positioning:

• Common bacterial infections: Along with conventional antibiotics Amoxicillin+clavulanic Acid


will be a good option to treat common bacterial infectious diseases

• Resistant pathogens: Best combination to treat infections caused by penicillin resistant pathogens
as well as beta lactamase producing pathogens

• Surgical prophylaxis: Prevent post-operative infections in surgical prophylaxis

• Sequential therapy: Ensures same efficacy when switched from intravenous to oral
Strength wise promotional focus:
Strength & Dosage Promotional focus
Form

CLACIDO 375/625 mg  Mild to moderate infections


tablet

 Severe infections
CLACIDO 625 mg/
1 g tablet  Sequential therapy because its ensures same efficacy when switched
from parenteral to oral

CLACIDO PFS/bid PFS  Excellent BANANA flavor

 Surgical prophylaxis
CLACIDO 0.6/1.2 g
Inj.  Severe infections
Key messages
 Outstanding coverage against pathogens cause - S. pneumoniae,
H. influenzae & M.catarrhalis
 Class leading activity against penicillin resistant S. pneumoniae
 High activity against anaerobes bacteria those are mainly responsible for chronic
sinusitis
 100% clinical efficacy in dental surgery
 94% clinical efficacy in general surgery
 94% clinical efficacy in abdominal & gynecological surgery
 96% clinical efficacy in biliary surgery

You might also like